New Home Company Inc (NWHM) Drops 5.38% on February 08

Equities Staff |

New Home Company Inc (NWHM) was one of the Russell 2000's biggest losers for Monday February 08 as the stock slid 5.38% to $7.91, a loss of $-0.45 per share. Starting at an opening price of $8.24 a share, the stock traded between $7.81 and $8.35 over the course of the trading day. Volume was 86,862 shares over 601 trades, against an average daily volume of 95,010 shares and a total float of 16.52 million.

The losses send New Home Company Inc down to a market cap of $130.65 million. In the last year, New Home Company Inc has traded between $17.97 and $8.35, and its 50-day SMA is currently $11.62 and 200-day SMA is $14.23.

The stock has a P/E Ratio of 9.3.

The New Home Company Inc is a homebuilding company, engaged in the design, construction and sale of consumer-driven homes in metropolitan areas within select growth markets in California.

New Home Company Inc is based out of Aliso Viejo, CA and has some 234 employees. Its CEO is H. Lawrence Webb.

For a complete fundamental analysis analysis of New Home Company Inc, check out’s Stock Valuation Analysis report for NWHM. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


A peer-to-Peer authentic photo marketplace disrupting the $10B commercial photography industry.


Uber connects riders with safe, reliable, convenient transportation providers at a variety of price-points in cities around the world. Uber makes money from charging their drivers 20% of the fare…